Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

Bibliographic Details
Main Authors: Miles, D., Chan, Arlene, Dirix, L., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J., Provencher, L., Puglisi, F., Harbeck, N., Steger, G., Schneeweiss, A., Wardley, A., Chlistalla, A., Romieu, G.
Format: Journal Article
Published: American Society of Clinical Oncology 2010
Online Access:http://hdl.handle.net/20.500.11937/6136

Internet

http://hdl.handle.net/20.500.11937/6136

Similar Items